AU3764593A - CCK and/or gastrin receptor ligands - Google Patents
CCK and/or gastrin receptor ligandsInfo
- Publication number
- AU3764593A AU3764593A AU37645/93A AU3764593A AU3764593A AU 3764593 A AU3764593 A AU 3764593A AU 37645/93 A AU37645/93 A AU 37645/93A AU 3764593 A AU3764593 A AU 3764593A AU 3764593 A AU3764593 A AU 3764593A
- Authority
- AU
- Australia
- Prior art keywords
- cck
- receptor ligands
- gastrin receptor
- gastrin
- ligands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929206757A GB9206757D0 (en) | 1992-03-27 | 1992-03-27 | Novel peptide receptor ligands |
| GB9206757 | 1992-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3764593A true AU3764593A (en) | 1993-11-08 |
Family
ID=10712996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU37645/93A Abandoned AU3764593A (en) | 1992-03-27 | 1993-03-25 | CCK and/or gastrin receptor ligands |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3764593A (en) |
| GB (1) | GB9206757D0 (en) |
| WO (1) | WO1993020099A2 (en) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU222178B1 (en) * | 1993-08-10 | 2003-04-28 | James Black Foundation Ltd. | Gastrin and cck receptor ligands, preparation thereof and pharmaceutical compositions containing them |
| US5795907A (en) * | 1994-05-27 | 1998-08-18 | James Black Foundation Limited | Gastin and CCK receptor ligands |
| KR100241643B1 (en) | 1995-06-06 | 2000-03-02 | 디. 제이. 우드 | Substituted N- (indole-2-carbonyl) -β-alanimamide and its derivatives for treating diabetes |
| JP3068200B2 (en) | 1995-06-06 | 2000-07-24 | ファイザー・インコーポレーテッド | Substituted N- (indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| WO1996039384A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| GB9610974D0 (en) * | 1996-05-24 | 1996-07-31 | Zeneca Ltd | Herbicides |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| TW527355B (en) | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| JP3943332B2 (en) * | 1997-12-23 | 2007-07-11 | アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） | Tripeptidyl peptidase inhibitor |
| US5955471A (en) * | 1998-01-13 | 1999-09-21 | Sk Corporation | Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same |
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| EP1114822A3 (en) * | 1998-06-03 | 2002-11-13 | Cortech Inc. | Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors |
| KR20010078724A (en) * | 1998-06-03 | 2001-08-21 | 존 더블류. 갈루치 2세 | Indole and Tetrahydroisoquinoline Containing α-Keto Oxadiazoles As Serine Protease Inhibitors |
| CO5140073A1 (en) | 1998-10-08 | 2002-03-22 | Smithkline Beecham Plc | DERIVATIVES OF 2,3,4,5-TETRAHIDRO-1H-3-BENZAPINA |
| CA2347912A1 (en) | 1998-12-18 | 2000-06-22 | Soo S. Ko | Heterocyclic piperidines as modulators of chemokine receptor activity |
| US6331541B1 (en) | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6525069B1 (en) | 1998-12-18 | 2003-02-25 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6444686B1 (en) | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| DE69926919D1 (en) | 1998-12-18 | 2005-09-29 | Bristol Myers Squibb Pharma Co | N-UREIDOALKYLPIPERIDINES AS MODULATORS OF THE ACTIVITY OF CHEMOKIN RECEPTORS |
| US6897234B2 (en) | 1999-12-17 | 2005-05-24 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| SE0000382D0 (en) | 2000-02-07 | 2000-02-07 | Astrazeneca Ab | New process |
| WO2001085695A1 (en) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| CA2413245A1 (en) | 2000-06-30 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| US6277877B1 (en) | 2000-08-15 | 2001-08-21 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors |
| AU2002357692A1 (en) | 2001-11-09 | 2003-05-26 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| DE60312516T2 (en) | 2002-06-14 | 2007-11-22 | Merck & Co., Inc. | INHIBITORS OF MITOTIC KINESINE |
| ATE446094T1 (en) | 2002-06-14 | 2009-11-15 | Merck & Co Inc | MITOTIC KINESIN INHIBITORS |
| ATE421512T1 (en) | 2003-08-15 | 2009-02-15 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESIN |
| EP1656133A4 (en) | 2003-08-15 | 2008-10-29 | Merck & Co Inc | Mitotic kinesin inhibitors |
| CN1835756A (en) | 2003-08-15 | 2006-09-20 | 默克公司 | Mitotic kinesin inhibitors |
| FR2876102A1 (en) * | 2004-10-04 | 2006-04-07 | Solvay | ENANTIOPUR HETEROCYCLIC COMPOUND |
| JP5121346B2 (en) * | 2007-08-07 | 2013-01-16 | 国立大学法人 長崎大学 | Optically active proline ester derivative and method for producing N-formyl optically active proline derivative |
| NO2513053T3 (en) | 2009-12-18 | 2018-03-03 | ||
| EP2661433B1 (en) | 2011-01-04 | 2017-08-16 | Novartis AG | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
| SG10201700328YA (en) | 2011-10-14 | 2017-02-27 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| ES2572908T3 (en) | 2011-10-14 | 2016-06-03 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline compounds substituted as factor XIa inhibitors |
| WO2014002053A1 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| JP6214647B2 (en) | 2012-06-28 | 2017-10-18 | ノバルティス アーゲー | Complement pathway modulators and uses thereof |
| EP2867226B1 (en) | 2012-06-28 | 2018-11-14 | Novartis AG | Complement pathway modulators and uses thereof |
| JP6154897B2 (en) | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | Pyrrolidine derivatives and their use as complement pathway regulators |
| ES2647124T3 (en) | 2012-06-28 | 2017-12-19 | Novartis Ag | Pyrrolidine derivatives and their use as modulators of the complement pathway |
| ES2687983T3 (en) | 2012-07-12 | 2018-10-30 | Novartis Ag | Modulators of the complement path and uses thereof |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| NZ707990A (en) | 2012-10-12 | 2018-07-27 | Bristol Myers Squibb Co | Crystalline forms of a factor xia inhibitor |
| JP6479763B2 (en) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Substituted azole containing tetrahydroisoquinolines as factor XIA inhibitors |
| BR112016011917B1 (en) | 2013-11-27 | 2022-10-11 | Epics Therapeutics | COMPOUNDS, COMPOSITION AND PHARMACEUTICAL METHODS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES |
| NO2760821T3 (en) | 2014-01-31 | 2018-03-10 | ||
| ES2893251T3 (en) | 2014-01-31 | 2022-02-08 | Bristol Myers Squibb Co | Macrocycles with heterocyclic P2' groups as factor XIa inhibitors |
| JP2017507184A (en) | 2014-02-25 | 2017-03-16 | アキリオン ファーマシューティカルズ，インコーポレーテッド | Phosphonate compounds for the treatment of complement-mediated disorders |
| JP6526796B2 (en) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Diamide macrocycles that are FXIA inhibitors |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| ES2809208T3 (en) * | 2015-06-25 | 2021-03-03 | Promega Corp | Thienopyrrole compounds and uses thereof as luciferase inhibitors from Oplophorus |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| AR105808A1 (en) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| AR105809A1 (en) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| ES2902006T3 (en) | 2016-06-27 | 2022-03-24 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders |
| EP3589628A4 (en) | 2017-03-01 | 2021-03-31 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2018160892A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| EP3684767B1 (en) | 2017-09-22 | 2024-04-24 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| FI3697785T3 (en) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
| CN111386265A (en) | 2017-11-06 | 2020-07-07 | 朱比连特普罗德尔有限责任公司 | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| IL274762B2 (en) | 2017-11-24 | 2023-10-01 | Jubilant Episcribe Llc | Novel heterocyclic compounds as prmt5 inhibitors |
| KR20200131845A (en) | 2018-03-13 | 2020-11-24 | 주빌런트 프로델 엘엘씨 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
| GB201810486D0 (en) * | 2018-06-26 | 2018-08-08 | Imperial Innovations Ltd | Natural killer cells |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| CA3111810A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of dancopan |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| KR20210093855A (en) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | Conformational forms of complement factor D inhibitors |
| WO2023164238A1 (en) * | 2022-02-25 | 2023-08-31 | Regents Of The University Of Minnesota | Protease inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU614716B2 (en) * | 1985-08-14 | 1991-09-12 | G.D. Searle & Co. | Phenyl substituted dipeptide amides |
| EP0288965A2 (en) * | 1987-04-29 | 1988-11-02 | Hoechst Aktiengesellschaft | Peptides with a phospholipase A2 inhibiting activity |
| CA1326108C (en) * | 1988-04-12 | 1994-01-11 | Sun Hyuk Kim | Cck antagonists |
| US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
| IE902238A1 (en) * | 1989-06-30 | 1991-01-16 | Abbott Lab | Tetrapeptide type-b cck receptor ligands |
| JPH05506643A (en) * | 1990-02-09 | 1993-09-30 | ローン―プーラン・ロレ・ソシエテ・アノニム | N-phenyl-N-acetamidoglycinamides, their production and drugs containing them |
-
1992
- 1992-03-27 GB GB929206757A patent/GB9206757D0/en active Pending
-
1993
- 1993-03-25 AU AU37645/93A patent/AU3764593A/en not_active Abandoned
- 1993-03-25 WO PCT/GB1993/000614 patent/WO1993020099A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| GB9206757D0 (en) | 1992-05-13 |
| WO1993020099A3 (en) | 1993-11-25 |
| WO1993020099A2 (en) | 1993-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3764593A (en) | CCK and/or gastrin receptor ligands | |
| AU2317195A (en) | Cck and gastrin receptor ligands | |
| ZA954315B (en) | Gastrin and cck antagonists | |
| EP0714292A4 (en) | Sigma receptor ligands and the use thereof | |
| AU3461293A (en) | Benzodiazepine derivatives, as CCK and gastrin antagonists | |
| ZA937790B (en) | Hydrocarbons | |
| AU4967793A (en) | Thienodiazepine derivatives as cholecystokinin and gastrin antagonists | |
| GB9519419D0 (en) | Particulate materials | |
| GB9210517D0 (en) | Coated particles | |
| AU3652093A (en) | Screening device | |
| GB9204249D0 (en) | Hinge | |
| GB9226006D0 (en) | Hinge assembly | |
| AU4872493A (en) | Mat | |
| ZA945998B (en) | Gastrin and CCK receptor ligands | |
| GB2303369B (en) | Cck and gastrin receptor ligands | |
| GB9502503D0 (en) | Gastrin and CCK antagonists | |
| GB2265665B (en) | Pivot fittings | |
| HUT66795A (en) | Release coat | |
| AU3212393A (en) | Cdnas encoding the gastrin and cck-b receptors | |
| GB9226341D0 (en) | Hinge | |
| GB9226749D0 (en) | Hinge | |
| IL104307A0 (en) | Hinge | |
| GB9215840D0 (en) | Hinge | |
| AU116874S (en) | Hinge | |
| GB9224373D0 (en) | Hinge |